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ABSTRACT
Objective While the long-term prognosis of autoimmune pancreatitis remains unclear, diagnosis of various malignant neoplasms 
has been reported in several autoimmune pancreatitis case studies. We retrospectively investigated the relationship between type 1 
autoimmune pancreatitis and the occurrence of malignant neoplasms. Methods Seventy-eight type 1 autoimmune pancreatitis patients 
were the subjects of this study. We investigated their clinical profiles, incidence of malignancies, and possible risk factors for developing 
malignancies, including duration of autoimmune pancreatitis, diabetes mellitus, and steroid therapy. Results Twelve patients developed 
malignancies after the diagnosis of autoimmune pancreatitis: colon cancer in five patients, lung cancer, pancreatic cancer and gastric 
cancer in two patients each, and hepatocellular cancer in one patient. In seven of the 12 patients (58.3%) a malignancy was detected 
within one year after the diagnosis of autoimmune pancreatitis. There were significant differences in gender, median age, and diffuse 
type of pancreas swelling between the group of patients with malignancies and the group without malignancies, but steroid therapy and 
diabetes mellitus were unrelated to the occurrence of malignancies in autoimmune pancreatitis. Conclusion The incidence of colon cancer 
in the type 1 autoimmune pancreatitis patients was higher than the incidence of other malignancies. Male, advanced age, and diffuse 
type of pancreatic swelling may be risk factors for malignancy in patients with type 1 autoimmune pancreatitis. It is recommended that 
male autoimmune pancreatitis patients over 70 years old who have been diagnosed with autoimmune pancreatitis within the previous 
year be examined for malignancy by a combination of gastrointestinal endoscopy, either chest X-ray or computed tomography scan, and 
abdominal ultrasound.
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INTRODUCTION
The concept of autoimmune pancreatitis (AIP) was first 
proposed by Yoshida et al. [1] in 1995 as a specific from 
of chronic pancreatitis that responds to corticosteroid 
treatment. Clinically, AIP is characterized by diffuse 
pancreatic enlargement and narrowing of the main 
pancreatic duct. Hamano et al. [2] discovered elevated 
serum IgG4 levels in AIP patients, and the serum IgG4 levels 
were sensitive biomarkers of AIP. AIP is classified into 2 
types based on its pathological features [3]. Type 1 AIP 
is characterized by IgG4-positive plasma cell infiltration 
around the pancreatic duct, obliterative phlebitis, and 
storiform fibrosis, and type 2 AIP is characterized by 
granulocytic epithelial lesions (GELs). IgG4-positive 
plasma cells are not found in type 2 AIP. Extrapancreatic 
lesions, including sclerosing cholangitis, retroperitoneal 
fibrosis, and sclerosing sialodenitis, sometimes occur in 
type 1 AIP, and they respond to steroid therapy [4]. 
The short-term prognosis of type 1 AIP is improved 
by steroid therapy, and since steroid withdrawal results 
in AIP relapse [5], in Japan AIP patients receive long-term 
steroid therapy. In other countries, however, AIP patients 
have also been treated with immunosuppressant therapy 
and anti-CD20 antibody therapy [6]. While the long-term 
prognosis of AIP remains unclear, the development of 
various malignant neoplasms, including pancreatic cancer 
[7, 8], colon cancer, gastric cancer [9, 10, 11, 12], and 
lymphoma [13, 14, 15], has been reported in AIP patients 
in several case studies and retrospective studies. Although 
whether AIP is associated with a higher incidence of 
malignant neoplasms is unknown [16, 17], Shiokawa et 
al. [18] reported finding that AIP patients are at high risk 
of various cancers and suggested that they may develop a 
paraneoplastic syndrome.
In this study, we retrospectively investigated the 




This study was carried out in accordance with the 
Declaration of Helsinki and was approved by the Institutional 
Review Board of Tokyo Women’s Medical University. The 
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cases of 78 patients who were diagnosed with type 1 AIP 
based on the International Consensus Diagnostic Criteria 
(ICDC) and Japan diagnostic criteria at Tokyo Women’s 
Medical University Hospital during the period between April 
2000 and February 2015 were retrospectively reviewed 
to determine their incidence of malignant neoplasms and 
to identify risk factors. They were followed up regularly, 
including by performing a range of examinations and 
collecting clinical data, including serum IgG4 levels and 
serum tumor marker levels, and computed tomography (CT) 
examinations. Malignant neoplasms were diagnosed based 
on the clinical data and pathological evidence. 
Malignant Neoplasms of the AIP Patients
We analyzed the characteristics of the AIP patients 
with malignant neoplasms, including their age and sex, 
and presence or absence of steroid therapy, diabetes 
mellitus (DM), the time malignancies were detected, and 
relapse of AIP after treating the malignancies. We also 
investigated whether the time when the malignancies 
were detected was associated with the type of malignancy, 
serum IgG4 level, relapse of AIP, steroid therapy, family 
history of malignancies, and diagnostic imaging findings 
in the pancreas. Since steroid therapy and DM are known 
risk factors for malignancy, we investigated whether total 
steroid dose and the presence of DM were associated with 
the development of malignancies in the AIP patients. 
Statistical Analysis
Continuous data were analyzed for significant differences 
by the χ2 test and Wilcoxon test, and Fisher’s exact test 
was used for categorical data. The statistical analysis was 
performed using the JMP version 12.0 software (SAS Institute 
Inc., Cary, NC). All statistical tests were two-sided, and a p 
value <0.05 was considered statistically significant.
RESULTS
Patient Characteristics
Twelve (15.4%) of the 78 type 1 AIP patients developed 
a malignant neoplasm. Their follow-up periods after the 
diagnosis of type 1 AIP ranged from 959 to 8223 days 
(Table 1). Their median age was 70 years. Ten patients 
had received steroid therapy when the malignancy 
was detected. The median serum IgG4 level of the 12 
patients at the time AIP was diagnosed was 535 mg/dl, 
and the range was 12-2370 mg/dl. DM was present in 7 
patients, and 6 patients had a family history of malignant 
neoplasms. Eight patients had an extrapancreatic lesion 
other than bile duct stenosis in the pancreas. The diffuse 
type of pancreatic swelling was present in 9 cases, and the 
focal type was present in 3 cases. There were significant 
differences in gender, median age, and type of pancreatic 
swelling between the group of AIP patients with malignant 
neoplasms and the group without malignant neoplasms, 
but there were no significant differences between the 
group in whether they had received steroid therapy, had 
DM, extrapancreatic lesions, a relapse of AIP, or a family 
history of malignancies, or in their serum IgG4 levels. 
The logistic multivariate analysis showed a significant 
difference in type of pancreatic swelling (Table1). 
The most common malignancy was colon cancer, which 
was diagnosed in 5 cases (41.7%), and it was followed by lung 
cancer, pancreatic cancer, and gastric cancer in 2 cases each 
(16.7%), and hepatocellular cancer in 1 case (8.3%). 
Time the Malignant Neoplasms Were Diagnosed in 
Relation to the Time Type 1 AIP was Diagnosed
We investigated whether there were differences 
between the group of patients with malignant neoplasms 
that had been diagnosed within 1 year after the diagnosis 
of AIP and the group of patients with malignant neoplasms 
that had been diagnosed more than 1 year after the 
diagnosis of AIP (Table 2). Twelve of the 78 AIP patients 
had developed a malignancy. The malignancy had been 
detected within a year after the diagnosis of AIP in 7 (9.0%) 
of the 78 patients, and they accounted for 58.3% of the 12 
AIP patients with a malignancy.
Five of the 78 AIP patients had been diagnosed with a 
malignancy more than a year after the diagnosis of AIP, and 
Characteristics
Cancer cases (%) Non-cancer cases (%)                    P value




Follow-up period (days; range) 2746 (959-8223) 2642  (570-7300) 0.532  
Gender (male/female) 12/0 42/24 0.014 0.188
Median age (years; range) 70 (43-80) 64 (37-82) 0.011 0.031
Steroid treatment (yes/no) 10/2 59/7 0.546
Serum IgG4 level when AIP diagnosed  (mg/dl; range) 12-2370(Median: 535)
3.5-8600          
(Median: 787) 0.678
Diabetes mellitus (yes/no) 7/5 45/21 0.632
Family history of malignant neoplasm (yes/no) 6/6 20/46 0.183
Relapse of AIP (yes/no) 3/9 18/48 0.87
Extrapancreatic lesion (yes/no)   (other than bile duct stenosis  
in the pancreas) 8/4 30/36 0.176
Findings of pancreas (diffuse/focal type) 9/3 24/42 0.013 0.014
Table 1. Characteristics of type 1 AIP patients with or without malignant neoplasms.
Univariate analysis calculated the characteristics of cancer patients and non-cancer patients. Logistic multivariate analysis calculated gender, median age 
and findings of pancreas, which are items that were significantly different in univariate analysis.
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another 5 patients had been diagnosed with a malignancy 
before the diagnosis of AIP, and thus the 7 AIP patients 
whose malignant neoplasms were detected within a year 
after the diagnosis of AIP formed the largest group. We 
compared the frequency of malignant neoplasms in both 
the groups. There were 3 cases of colon cancer, and one 
case each of lung cancer, pancreatic cancer, gastric cancer, 
and hepatocellular cancer in patients whose malignant 
neoplasms were detected more than a year after the 
diagnosis of AIP. There were 2 cases of colon cancer and 
1 case each of lung cancer, pancreatic cancer, and gastric 
cancer in patients whose malignant neoplasms were 
detected malignant neoplasms more than a year after the 
diagnosis of AIP. The incidence of colon cancer among 
the AIP patients was higher than the incidences of the 
other cancers, and there were no statistically significant 
differences between the both the groups with respected to 
types of malignancies. 
Treatment of the Malignant Neoplasms and Relapse of 
AIP after Cancer Treatment
Ten of the 12 patients underwent surgery or endoscopic 
mucosal resection (EMR) for a malignant neoplasm that 
was detected after the diagnosis of AIP, and 2 of them had 
pancreatic cancer. One of the 2 patients with pancreatic 
cancer received adjuvant chemotherapy after surgery, and 
the other patient underwent surgery alone. Five patients 
had colon cancer, and one of them underwent EMR. We 
discontinued steroid maintenance therapy in four of the 
10 patients, but none of them experienced a postoperative 
relapse. Because of their poor performance status the 2 
lung cancer patients could not be treated surgically or by 
chemotherapy. 
Histological Findings and Stage of Malignant Neoplasms
Two of the 5 patients in the present study who 
developed colon cancer had stage IIIA, and one each had 
stage IIIB, stage I, and carcinoma in situ. One of 2 patients 
with pancreatic cancer had stage I, and the other had stage 
III. One of the 2 patients with gastric cancer had stage I. 
The one patient with hepatocellular carcinoma had stage 
III. Both patients with lung cancer had unresectable 
advanced stage. The pancreatic cancer in both patients 
was detected in the resectable stage. One pancreatic cancer 
patient presented with stenosis of the pancreatic duct; 
the preoperative pathological diagnosis was high-grade 
dysplasia. Histological findings of the surgical specimen 
revealed pancreatic cancer cells in the small part of main 
pancreatic duct, with diffuse inflammatory IgG4-positive 
plasma cells, lymphocytes infiltration, and obliterative 
phlebitis in the pancreatic head. The other pancreatic 
cancer patient presented with atrophic pancreas and 
infiltrated IgG4-positive plasma cells and lymphocytes 
around the main pancreatic duct. Cancer cells were 
detected in the pancreatic head, which metastasized to the 
lymph nodes. 
Total Steroid Dose and Duration of DM
The total steroid dose varied. Three of the 12 patients 
who developed malignancies after the diagnosis of AIP 
had not received steroid therapy, and the other 9 patients 
(75%) had received total steroid doses of 2.9-15.9 g. Nine 
of the 12 patents had received steroid therapy (Table 3), 
and maintenance steroid therapy was continued in 8 of the 
9 patients. To clarify the effect of steroid therapy on the 
risk of malignancy, we compared the total steroid doses 
of the group of AIP patients with a malignancy that had 
been detected after the diagnosis of AIP and the group of 
AIP patients in whom a malignancy had not been detected 
(Figure 1). The differences between the total steroid 
doses of the two groups were not statistically significant, 
suggesting that steroid therapy does not promote the 
development of malignancy and is not a risk factor for 
malignancy in AIP patients. Finally, we investigated the 
association between the presence of DM and occurrence of 
malignancies in AIP patients, but the results showed that 
the presence of DM was not associated with an increase 
the incidence of malignancy (Table 1). 
DISCUSSION
Previous studies have reported malignancy prevalence 
of 10.4%-18% in AIP patients [18, 19, 20, 21], a prevalence 
range that was consistent with our own findings in the 
present study, and the most frequent type of malignancy 
in the AIP patients in the previous studies was colon 
cancer, which was followed by lung cancer and then 
gastric cancer. A recent multicenter international analysis 
revealed that malignant neoplasms had been found in 57 of 
978 type 1 AIP patients, and the most frequent malignancies 
in descending order of incidence were gastric cancer, lung 
cancer, prostate cancer, colon cancer, and pancreatic cancer 
[17]. Earlier studies also reported higher incidences of gastric 
cancer, lung cancer, and colon cancer than pancreatic cancer 
in Japanese AIP patients [18, 20, 22, 23]. It seems that patients 
who regularly attend a hospital clinic because of AIP are 
more likely than healthy subjects to receive gastrointestinal 
endoscopic examinations and that may have led to early 
detection of their gastrointestinal cancers.
A malignant neoplasm was detected within a year after 
the diagnosis of AIP in 9.0% of the 78 type 1 AIP patients in 
the present study, and they accounted for 58.3% of the 12 
Time of diagnosis of the malignant neoplasm Cases (all type 1 AIP patients; %) Proportion of type 1 AIP patients with  malignancies: %
Before diagnosis of AIP 5 (6.4) -
Within 1 year after diagnosis of AIP　 7 (9.0) 58.3
More than 1 year but no more than 5 years after diagnosis of AIP 1 (1.3) 8.3
More than 5 years but no more than 10 years after diagnosis of AIP 3 (3.8) 25
Ten years or more after diagnosis of AIP 1 (1.3) 8.3
Table 2. Time of malignant neoplasm diagnosis in relation to the time of AIP diagnosis.
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Relapse of AIP after 
cancer treatment




Time of detection of the malignant 
neoplasm in relation to the diagnosis 
of AIP
1 pancreatic neoplasm surgery - 5 13.9 9 years after
2 pancreatic neoplasm※ surgery - - 0 synchronous
3 stomach neoplasm EMR - 5 4.1 3 year after
4 stomach neoplasm surgery - 10 5.2 within 1 year
5 liver neoplasm surgery - 7.5 2.9 within 1 year
6 colon neoplasm surgery - - 6.7 20 years after
7 colon neoplasm surgery - - 0 synchronous
8 colon neoplasm surgery - 4 3.9 within 1 year
9 colon neoplasm surgery - 5 15.9 8 years after
10 colon neoplasm EMR - 2.5 2.4 synchronous
11 lung neoplasm - - - 0 synchronous
12 lung neoplasm - - 4 19.9 7 years after
Table 3. Characteristics of the 12 type 1 AIP patients with malignant neoplasms.




















Figure 1. Analysis of the relation between total steroid dose administered to AIP patients and the development of malignant neoplasms
The line above the boxes and the line below the boxes indicate the first quartile and the fourth quartile, respectively. The length of each box represents the 
interquartile range, and 50% of the values are located within it.
AIP patients in whom a malignancy had been detected after 
the diagnosis of AIP. The incidence of malignant neoplasms 
tended to be higher within a year after the diagnosis of AIP, 
and there were no AIP relapses after cancer treatment, 
suggesting that the development of malignant neoplasms 
among AIP patients is associated with the occurrence of 
autoimmune disease. 
While it is unclear why malignant neoplasms often 
develop within a year after the diagnosis of AIP, there are 
several hypotheses to explain the association between 
malignancies and AIP. First, chronic inflammatory disease 
causes malignancies such as colitic cancer in ulcerative 
colitis, hepatocellular carcinoma in hepatitis C, and 
pancreatic cancer in chronic pancreatitis [24]. Kamisawa 
et al. reported detecting more frequent K-ras mutations 
in the gastric and colonic mucosae of AIP patients as well 
as in their pancreatic epithelia [25, 26]. Mutationally 
activated K-ras is the earliest genetic mutation in 
precancerous lesions and has been found in more than 
95% of pancreatic cancer patients and in 27% of chronic 
pancreatitis patients. Based on these findings, oncogenic 
K-ras mutations are thought to promote gastric and colon 
cancer in AIP patients. While K-ras mutation is an early step 
in the progression toward pancreatic cancer, the incidence 
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of pancreatic cancer was lower than the incidences of other 
gastrointestinal cancers in the present study as well as in 
previous studies [18, 19, 20, 23]. Pancreatic intraepithelial 
neoplasia (PanIN) is recognized as the precursor lesion of 
invasive pancreatic cancer, and activated K-ras mutations 
are almost always present in the early stage of PanIN. 
Gapta et al. have reported detecting PanIN and PanIN 
2 in 82% and 25%, respectively, of AIP cases [27]. Their 
reports support the hypothesis that AIP is associated with 
an increased risk of malignancy. Pancreatic cancer was 
diagnosed in 2 of the 78 AIP patients in our study. One of 
the 2 patients with pancreatic cancer had both a history of 
three cancers in different organs before the diagnosis of 
AIP, and a family history of pancreatic cancer, suggesting 
that genetic factors play a major role in the development 
of pancreatic cancer. The pancreatic cancer in the other 
patient was diagnosed 9 years after the diagnosis of AIP, 
and the patient had received steroid maintenance therapy 
for 9 years because of repeated AIP relapses. Thus, K-ras 
mutations and PanIN lesions are likely to be involved in 
the progression of malignancies in patients with a longer 
duration of AIP.
The second hypothesis to explain the development 
of malignancies in AIP is the existence of an 
immunosuppressed state induced by steroid therapy. 
Long-term administration of immunosuppressive drugs 
such as azathioprine has been reported to increase the risk 
of carcinogenesis [28]. Although 10 of the 12 AIP patients 
found malignant neoplasms within 1 year after diagnosis 
of AIP in our study had received steroid therapy, two 
patients who had not received steroid therapy after being 
diagnosed with AIP developed malignancies. Although the 
total steroid doses received by the group of AIP patients 
with malignancies and the group of AIP patients without 
malignancies were not significantly different according to 
the results of a univariate analysis, there were significant 
differences according to the results of a multivariate 
analysis. Hirano et al. reported finding that univariate 
analysis identified age at onset of IgG4-RD >65 years and 
the presence of DM as significant risk factors for malignancy 
in patients with IgG4-related disease, but that DM was 
not found to be a significant risk factor in a multivariate 
analysis [20]. Consistent with their results, the difference 
between the incidences of malignancies in the group of AIP 
patients with DM and the group of AIP patients without DM 
in our own study was not statistically significant. A study 
by Shimizu et al. found that 6 out of 9 patients developed a 
malignancy after the diagnosis of AIP, but steroid therapy 
was administered after development of the malignancy in 
all 6 cases. These results suggest that steroid therapy itself 
does not increase the risk of malignancies in AIP. 
A third hypothesis to explain the development of 
malignancies in AIP is that the immunological response 
that the malignant neoplasm itself induces promotes the 
infiltration by IgG4-positive plasma cells. Liu et al. reported 
observing that IgG4-positive plasma cells had infiltrated 
pancreatic cancer lesions and the surrounding area and 
that a high level of intratumoral IgG4-positive plasma 
cell infiltration was correlated with a poor outcome [29]. 
Fukui et al. also found that IgG4-positive cells infiltrated 
pancreatic cancer lesions, peritumoral pancreatitis lesions, 
and obstructive pancreatitis lesions along with pancreatic 
cancer and that the number of IgG4-positive cells or the 
ratio of IgG4-positive cells to IgG-positive cells was higher 
in the pancreas of AIP patients than of pancreatic cancer 
patients [30]. They also found a significant correlation 
between the numbers of regulatory T-cells (T-regs) and 
IgG4-positive cells in obstructive pancreatitis lesions. A 
similar immune mechanism appears to be involved in the 
production of IgG4-positive cells in AIP and in obstructive 
pancreatitis in pancreatic cancer. We therefore speculated 
that the development of AIP within a year after the diagnosis 
of malignancy is related to a cancer-associated immune 
response and that the development of a malignancy several 
years after the diagnosis of AIP is associated with chronic 
inflammation and/or a genetic mutation. 
Three of 5 colon cancers occurred within a year after 
the diagnosis of AIP, and we thought that they are related 
to the cancer-associated response. On the other hand, the 
other two of 5 colon cancers occurred after 8 years and 
20 years, and chronic inflammation was not found in their 
surgical specimens. As the incidence of colon cancer was 
generally high and colonoscopy was frequently performed 
during screening, we suspect that the number of colon 
cancer patients in our study was higher than that of patients 
with our study types of cancer. While it is important to 
clarify the immune mechanism of type 1 AIP regarding 
the development of colon cancer, the association between 
immune mechanism in type 1 AIP and the incidence of 
colon cancer in this study remain unclear. 
In conclusion, although the mechanism underlying 
the development of malignant neoplasms in AIP patients 
has yet to be identified, the incidence of malignancies was 
relatively high within a year after the diagnosis of AIP. 
Because of the high incidence of malignant neoplasms in 
AIP patients, it is recommended that male AIP patients 
over 70 years old who have been diagnosed with AIP 
within the previous year be examined for malignancy by 
a combination of gastrointestinal endoscopy, either chest 
X-ray or CT scan, and abdominal ultrasound.
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